Long-term survival outcomes of neoadjuvant chemotherapy in stage II-III HR+/HER2- breast cancer

Long-term survival outcomes of neoadjuvant chemotherapy in stage II-III HR+/HER2- breast cancer

Abstract Breast cancer is the most common malignant tumor among women worldwide. Hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer is the largest subgroup among these cases. The application of neoadjuvant chemotherapy (NACT) has rapidly increased in recent years, but its impact on lo...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiaxing Liu, Likuan Tan, Hongyu Zhang, Chengzhi Ma, Gang Qin, Shaolong Huang, Yang Long, Feng-hui He, Yao Huang, Miao-Miao Jiao, Yufei Liu, Guanghui Wang
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Breast cancer
HR+/HER2-
Neoadjuvant chemotherapy
Overall survival
Breast cancer-specific survival
Propensity score matching
Online Access:https://doi.org/10.1038/s41598-025-14012-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-14012-0

Similar Items